At AMCP Nexus 2026, Carmen Witsken, PharmD, discusses high upfront cell and gene therapy costs and the case for a national risk pool.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.